Access, cost, and policy

Regulatory approval means ustekinumab (Stelara) can now be prescribed in the EU for some children with moderate‑to‑severe Crohn’s disease who haven’t responded to other treatments. This expands treatment options for...

A new EC approval makes ustekinumab an approved treatment option for children and adolescents (≥40 kg) with moderate–severe Crohn’s disease, potentially expanding choices for patients who haven’t responded to other...

Based on the title and source metadata, this appears to be an observational study related to Inflammatory bowel disease and Access, cost, and policy. The original article is from msn.com.

A CHMP recommendation is a major regulatory step toward EU approval — that could mean a new biologic option (guselkumab/Tremfya) for adults with moderate–severe Crohn’s disease, including people who haven’t responded to...

This roundup highlights many drugs and trials in development for Crohn’s disease, including late‑stage studies of biologics and newer oral agents — information that could affect future treatment options. Patients on...

This report outlines which drugs and companies are shaping Crohn’s disease treatment options and predicts market shifts that may affect treatment availability, costs, and future therapy choices.

This FDA approval adds another biologic option (an IL-23 inhibitor) for adults with moderate-to-severe Crohn’s disease, including both self-administered subcutaneous dosing and an IV induction route. New options may...

Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from firstwordpharma.com.

This approval adds an FDA-cleared IL-23 biologic (Tremfya) as a treatment option for adults with moderately to severely active Crohn’s disease, which may affect treatment choices. It also comes as multiple biosimilars to...

A new FDA approval expands treatment options for adults with moderately to severely active Crohn’s disease, including a fully subcutaneous IL-23 inhibitor regimen that could offer more flexibility. The approval was based...

An FDA approval means a new biologic option (guselkumab/Tremfya) is available for adults with moderately to severely active Crohn’s disease and may change prescribing choices. The approval highlights a dosing flexibility...

A newly FDA‑approved IL‑23 drug for Crohn’s may increase treatment options for people with IBD, including an IV and a subcutaneous formulation. The approval could affect switching decisions for patients not responding to...

A newly FDA-approved biologic (guselkumab/Tremfya) offers another treatment option for adults with moderate to severe Crohn’s disease, including both IV and SC induction choices. This could matter for patients who have...

An FDA approval means TREMFYA is now an additional, officially authorized treatment option for adults with moderately to severely active Crohn's disease. The drug offers both IV and SC induction choices and established...

Cure8 found this source from fiercepharma.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab. Open the original article for the full details.

Cure8 could only read part of this source from nexstar.tv, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease, Crohn's disease, and Community and awareness.

Cure8 found this source from drugstorenews.com, but the page could not be read reliably yet. It is tagged for Ustekinumab, Biosimilars, and IL-12/23 inhibitor. Open the original article for the full details.

Denied or cut-off long-term disability benefits can create immediate financial stress for people with Crohn’s disease who cannot work. Knowing how to document your medical limitations and when to seek legal help can...

Disability benefits can help people with moderate-to-severe Crohn’s cover lost income and higher medical costs. The SSA has specific IBD-related criteria and medical examples that can support a claim, so understanding...

This highlights a local family’s experience with pediatric Crohn’s disease, showing how community support and Foundation programs can help patients and caregivers connect, fundraise, and access resources.

Cure8 could only read part of this source from managedhealthcareexecutive.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Ustekinumab, Biosimilars, and IL-12/23 inhibitor.

Based on the title and source metadata, this appears to be a patient education related to Access, cost, and policy. The original article is from msn.com.

Market reports highlight which drug classes and companies are investing in Crohn's disease — relevant for patients interested in treatment availability, new product development, or access issues. They can signal where...

Spanish-speaking people with Crohn’s disease or ulcerative colitis often lack culturally tailored, medically reviewed resources. A Spanish-language community can improve access to information, peer support, and...

Cure8 found this source from ksn.com, but the page could not be read reliably yet. It is tagged for Access, cost, and policy. Open the original article for the full details.

Cure8 found this source from ksn.com, but the page could not be read reliably yet. It is tagged for Access, cost, and policy. Open the original article for the full details.

Spanish-speaking people with Crohn’s disease or ulcerative colitis often face language and access barriers to care and information. A dedicated Spanish-language community can improve access to medically reviewed...

Cure8 could only read part of this source from cbsnews.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Access, cost, and policy.

Cure8 found this source from businesswire.com, but the page could not be read reliably yet. It is tagged for Ustekinumab, Biosimilars, and IL-12/23 inhibitor. Open the original article for the full details.

Crohn’s can sometimes cause flare-ups or complications that make working difficult or impossible; disability benefits can replace part of lost income. The article lays out the types of benefits and what the SSA looks for...

A CE mark under the EU IVDR means a new non-invasive test aimed at identifying dietary triggers for people with UC or Crohn’s may become available in Europe. Tests like this could affect how some patients and clinicians...

A new CE-marked food-intolerance diagnostic could give people with Crohn’s or UC a non-invasive tool to explore dietary triggers alongside clinical care. Regulatory certification means the products met EU safety and...

A new FDA‑approved biosimilar to ustekinumab is now available in the U.S., which may increase treatment options and lower out‑of‑pocket costs for people with Crohn’s disease or ulcerative colitis. The article highlights...

A new FDA‑approved ustekinumab biosimilar (YESINTEK) is now available in the US for Crohn’s disease and ulcerative colitis, which may increase treatment options and lower costs. Coverage and copay support at launch could...

Based on the title and source metadata, this appears to be a market or business news related to Access, cost, and policy. The original article is from msn.com.

Cure8 found this source from business-standard.com, but the page could not be read reliably yet. It is tagged for Ustekinumab, Biosimilars, and IL-12/23 inhibitor. Open the original article for the full details.

Cure8 could only read part of this source from devdiscourse.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Ustekinumab.

The article reports new phase 2 trial data for duvakitug, an experimental anti‑TL1A treatment for ulcerative colitis and Crohn’s disease, which helps compare it to rival candidates and shapes upcoming phase 3 plans.

Cure8 could only read part of this source from money.rediff.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Ustekinumab.

Changes in the therapeutics market can affect availability, pricing, and access to Crohn’s treatments. Growth in biosimilars and new drug approvals may influence what options become more widely available.

Cure8 found this source from financialexpress.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Biosimilars. Open the original article for the full...

Cure8 found this source from finance.yahoo.com, but the page could not be read reliably yet. It is tagged for Ustekinumab, Biosimilars, and IL-12/23 inhibitor. Open the original article for the full details.

A new ustekinumab biosimilar (SELARSDI) is now available in the U.S. for Crohn’s disease and ulcerative colitis, which may expand treatment options and affect access or cost for patients on biologic therapy.

Local fundraising events raise money and visibility for people living with Crohn’s and colitis and can connect patients, families, and supporters. Participating or volunteering supports the charity and can offer social...

The article summarizes a commercial market report that lists current and upcoming Crohn's disease treatments, trial results, and a biosimilar approval — information patients may see reflected in treatment availability,...

Ohio lawmakers are proposing limits on THC and higher taxes that could make cannabis less potent and more expensive. People with Crohn’s disease and other patients who rely on cannabis for symptom control could see...

Market reports highlight which companies and drug types are investing in Crohn's disease — that can signal upcoming therapies, trial activity, and availability. Mentions of trials (for example anti‑TL1A) may be of...

Cure8 found this source from onlinelibrary.wiley.com, but the page could not be read reliably yet. It is tagged for Crohn's disease and Procedures and surgery. Open the original article for the full details.